期刊文献+

α-突触核蛋白过表达转基因帕金森病动物模型研究进展 被引量:1

下载PDF
导出
摘要 帕金森病是最常见的神经变性疾病之一。帕金森病动物模型是解释疾病病因学根本机制,开发新的神经保护药物和治疗策略研究的必不可少的工具。该文综述了目前常用的几类帕金森病α-突触核蛋白过表达转基因动物模型及其优缺点。转基因动物模型是目前最为重要的帕金森病动物模型;较全面地反映帕金森病病因及发病机理、病理特点,将是帕金森病动物模型研究新时代的开始,也是今后研究探讨的方向。
作者 杨旭 彭国光
出处 《国际神经病学神经外科学杂志》 2012年第3期278-281,共4页 Journal of International Neurology and Neurosurgery
基金 重庆市医学科研计划重点项目(2009-1-58) 重庆医科大学附属第一医院医学科学基金项目(YXJJ2009-24)
  • 相关文献

参考文献18

  • 1McNaught KS, Olanow CW. Protein aggregation in the patho- genesis of familial and sporadic Parkinson ' s disease. Neurobi- ol Aging,2006,27(4) : 530-45.
  • 2Lehmensiek V, Tan EM, Schwarz J, et al. Expression of mutant alpha-synuclein enhances dopamine transporter--media- ted MPP + toxicity in vitro. Neuroreport, 2002, 13 ( 10 ) : 1279-1283.
  • 3Masliah E, Roekenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in a-synuclein mice: Impli- cations for neurodegenerative disorders. Science, 2000,287 (18) : 1265-1269.
  • 4Wu N, Joshi PR, Masliah E, et al. Aalpha-synuclein overex- pression in mice alters synaptic communication in the corticostria- tal pathway. J Neurosci Res ,2010,88(8) : 1764-1776.
  • 5Fleming SM, Tetreault NA, Masliah E, et al. Olfactory defi- cits in mice overexpressing human wild type alpha -synuclein. Eur J Neurosci,2008,28 (2) : 247 -256.
  • 6van der Putten H, Wiederhold KH, Probst A, el al. Neuro- pathology in mice expressing human alpha-synuelein. J Neu- rosci,2000,20(16) : 6021-6029.
  • 7Richfield EK, Thiruchelvam M J, Cory-sleehta DA, et al. Behavioural and neuroehemical effects of wild-type and muta- ted haman a/pha-synuclein in transgenic mice. Exp Neurol, 2002,175(1) : 35-48.
  • 8Matsuoka Y, Vila M, Lincoln S, et al. Lack of nigral pathology in transgenic mice expressing alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol, 2001 , 8 (3) : 535-539.
  • 9Giasson BI, Duda JE, Quirm SM, et al. Neuronal a-synuclei- nopathy with Severe Movement Disorder in Mice Expressing A53T Human a-synuclein. Neuron ,2002,5 (34) : 521-533.
  • 10Martin LJ, Pan Y, Price AC, et al. Parkinson' s Disease a- Synuclein Transgenie Mice Develop Neuronal Mitochondrial Degen- eration and Cell Death. J Neurosci ,2006,26( 1 ) : 41-50.

同被引文献22

  • 1Emborg ME, Moirano J, Raschke J, et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neu- robiol Dis, 2009, 36(2) : 303-311.
  • 2Zhuang X, Li X, Redus L, et al. Cognitive Dysfunction Precedes the Onset of Motor Symptoms in the MitoPark Mouse Model of Parkinson ' s Disease. PLoS ONE, 2013 , 8 ( 8 ) : e71341.
  • 3Covy JP, Giasson BI. alpha- Synuclein, leucine- rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Neurotoxicology, 2011 , 32 ( 5 ) : 622-629.
  • 4Muramatsu SI, Fujimoto KI, Kato S, et al. A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson ' s Disease. Molecular Therapy, 2010, 18 ( 9 ) : 1731-1735.
  • 5Christine CW, Start PA, Larson PS, et al. Safety and toler- ability of putaminal AADC gene therapy for Parkinson disease. Neurology, 2009, 73(20) : 1662-1669.
  • 6McFarland NR, Lee JS, Hyman BT, et al. Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochemistry, 2009, 109(3): 838-845.
  • 7Mosley RL, Ohshima-Hosoyama S, Simmons HA, et al. A Monoclonal Antibody-GDNF Fusion Protein Is Not Neuropro- tective and Is Associated with Proliferative Pancreatic Lesions in Parkinsonian Monkeys. PLoS ONE, 2012, 7 (6) : e39036.
  • 8Shi D, Chen G, Lv L, et al. The effect of lentivirus-media- ted TH and GDNF genetic engineering mesenchymal stem cells on Parkinson ' s disease rat model. Neurol Sci, 2010, 32 (1) : 41-51.
  • 9Biju KC, Zhou Q, Li G, et al. Macrophage-mediated GDNF Delivery Protects Against Dopaminergic Neurodegeneration: ATherapeutic Strategy for Parkinson' s Disease. Mol Ther, 2010, 18(8): 1536-1544.
  • 10Herr6n E, Ruiz-Ortega J(1, Aristieta A, et al. In vivo ad- ministration of VEGF- and GDNF-releasing biodegradable pol- ymeric microspheres in a severe lesion model of Parkinson ' s disease. Eur J Pharm Biopharm, 2013, 85 (3) : 1183- 1190.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部